BACKGROUND: @entity416 plus @entity901 (CapeOx)    bevacizumab therapy is associated with a high incidence of hand-foot skin reaction (HFSR), hindering treatment. However, timing of onset and risk factors remain unclear. OBJECTIVE: This study examined the development of HFSR and risk factors for its exacerbation to a serious condition in CapeOx    bevacizumab therapy. METHODS: We retrospectively examined @entity1 with @entity14 receiving CapeOx    bevacizumab therapy between October 1, 2009, and March 31, 2012. The observation period was defined as lasting until completion of 8 cycles. The relationship between cumulative dose of @entity416 and cumulative proportion of @entity1 developing HFSR was evaluated by Kaplan-Meier methods. Risk factors for exacerbation of HFSR to a serious condition were assessed by multiple logistic regression. RESULTS: Data for 203 @entity1 were analyzed. For @entity1 treated at cumulative @entity416 doses of 100 000 mg/m(2) and 200 000 mg/m(2), Grade 1 HFSR occurred in >= 80% and >= 90%, respectively, and moderate-to-severe HFSR (Grade 2+) occurred in >= 10% and >= 20%, respectively. Multivariate analysis showed significant associations with @entity6 (odds ratio [OR] = 4.79; 95% confidence interval [CI] = 1.86-12.34; P = 0.001), concomitant use of bevacizumab (OR = 6.01; 95% CI = 2.20-16.41; P = 0.001), history of fluorinated @entity7391 administration (OR = 2.42; 95% CI = 1.10-5.33; P = 0.027), and early onset (within 21 days) of Grade 1 HFSR (OR = 3.78; 95% CI = 1.64-8.70; P = 0.001). CONCLUSIONS: HFSR in CapeOx therapy is a cumulative @entity137 and risk of exacerbation to a serious condition increases with @entity6 , concomitant use of bevacizumab, history of fluorinated @entity7391 administration, and onset of Grade 1 HFSR within 21 days.

Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by XXXX plus @entity901    Bevacizumab Therapy.

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine', 'Capecitabine'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity7391 :: ('MESH:C030986', 'Chemical') :: ['pyrimidine']
@entity416 :: (MESH:C110904,Chemical) :: ['Capecitabine']
